Close Menu
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being

Subscribe to Updates

Subscribe to our newsletter and never miss our latest news

Subscribe my Newsletter for New Posts & tips Let's stay updated!

What's Hot

Amid disappointing earnings, Pinterest claims it sees more searches than ChatGPT

February 12, 2026

IBM will hire your entry-level talent in the age of AI

February 12, 2026

Scientific studies calculate climate change as health danger, while Trump calls it a ‘scam’

February 12, 2026
Facebook X (Twitter) Instagram
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
Facebook X (Twitter) Instagram
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
  • Home
  • AI
  • Education
  • Entertainment
  • Food Health
  • Health
  • Sports
  • Tech
  • Well Being
IQ Times Media – Smart News for a Smarter YouIQ Times Media – Smart News for a Smarter You
Home » FDA approves HIV prevention drug taken as twice-yearly injection
Health

FDA approves HIV prevention drug taken as twice-yearly injection

IQ TIMES MEDIABy IQ TIMES MEDIAJune 19, 2025No Comments2 Mins Read
Facebook Twitter Pinterest LinkedIn Tumblr Email
Share
Facebook Twitter LinkedIn Pinterest Email


The U.S. Food and Drug Administration has approved the drug lenacapavir as a twice-yearly injection to prevent HIV.

The drug, called Yeztugo from company Gilead Sciences, was approved Wednesday based on data from clinical trials that showed 99.9% of participants who received it remained HIV negative.

Daniel O’Day, Gilead’s chairman and chief executive officer, called the approval a “milestone moment in the decades-long fight against HIV.”

“Yeztugo will help us prevent HIV on a scale never seen before. We now have a way to end the HIV epidemic once and for all,” O’Day said in a news release.

According to the Centers for Disease Control and Prevention, there were 31,800 estimated new HIV infections in the United States in 2022, the most recent year with available data.

While the drug’s approval meets an existing need, the Trump administration’s funding decisions have rolled back progress for a vaccine.

Last month, the administration moved to end funding for a broad swath of HIV vaccine research, saying current approaches are enough to counter the virus.

Dr. Barton Ford Haynes, the director of the Duke Human Vaccine Institute, recently told CBS News lenacapavir is a “wonderful development for the field,” but said there was still a need for a vaccine.

“For HIV vaccine design and development, we’ve begun to see light at the end of the tunnel after many years of research,” Dennis Burton, an immunology professor at Scripps Research, previously told CBS News. “This is a terrible time to cut it off. We’re beginning to get close. We’re getting good results out of clinical trials.”

Burton warned that their HIV vaccine research could not simply be turned back on, even if a future administration decided to change course on HIV funding. He said ongoing experiments would be shuttered, and researchers assembled to study the issue would be forced to refocus their careers on other topics.

“This is a decision with consequences that will linger. This is a setback of probably a decade for HIV vaccine research,” Burton said.

Teen questioned after family’s quadruple murder

Iranians evacuate capital Tehran, some say the regime is frightened

Parents, brother of slain Minnesota lawmaker Melissa Hortman speak about her death



Source link

Share. Facebook Twitter Pinterest LinkedIn Tumblr Email
IQ TIMES MEDIA
  • Website

Related Posts

Scientific studies calculate climate change as health danger, while Trump calls it a ‘scam’

February 12, 2026

Harmful chemicals lurk in extensions and braiding hair marketed to Black women, study finds

February 12, 2026

Colorectal cancer is rising in younger adults. Here’s who is most at risk and symptoms to watch for

February 12, 2026
Add A Comment
Leave A Reply Cancel Reply

Editors Picks

Advances in education and community ties help Pennsylania steel town

February 12, 2026

BYU standout receiver Parker Kingston charged with first-degree rape in Utah

February 11, 2026

Yale suspends professor from teaching while reviewing his correspondence with Epstein

February 11, 2026

Gov. Gretchen Whitmer signs classroom smartphone ban for Michigan schools

February 11, 2026
Education

Advances in education and community ties help Pennsylania steel town

By IQ TIMES MEDIAFebruary 12, 20260

CLAIRTON, Pa. (AP) — At 2 p.m. on a chilly January afternoon, the elementary floor…

BYU standout receiver Parker Kingston charged with first-degree rape in Utah

February 11, 2026

Yale suspends professor from teaching while reviewing his correspondence with Epstein

February 11, 2026

Gov. Gretchen Whitmer signs classroom smartphone ban for Michigan schools

February 11, 2026
IQ Times Media – Smart News for a Smarter You
Facebook X (Twitter) Instagram Pinterest Vimeo YouTube
  • Home
  • About Us
  • Advertise With Us
  • Contact us
  • DMCA
  • Privacy Policy
  • Terms & Conditions
© 2026 iqtimes. Designed by iqtimes.

Type above and press Enter to search. Press Esc to cancel.